Heart Failure
43 articles on Heart Failure, written by Shotlee and medically reviewed for clinical accuracy.
People Taking GLP-1 Weight Loss Drugs Like Ozempic and Wegovy Started Moving Less
New data presented at ENDO 2026 reveals a paradox: patients on GLP-1 medications like Ozempic and Wegovy reduced their physical activity despite losing weight.
8 min read
Ozempic vs. Jardiance: Better Heart Protection for Diabetics with AFib
A new study compares GLP-1 and SGLT-2 inhibitors in patients with type 2 diabetes and atrial fibrillation, revealing significant differences in heart health outcomes.
7 min read
Medicare's GLP-1 Weight Loss Drug Bridge: What You Need to Know
For the first time, Medicare is expanding access to GLP-1 medications for weight loss through a new pilot program. Starting July 1, eligible beneficiaries can access popular drugs like Wegovy and Zepbound for a $50 monthly copay. This groundbreaking initiative aims to make these life-changing treatments more accessible, but understanding the specifics is crucial.
7 min read
Beyond Weight Loss: GLP-1 Drugs and Unexpected Changes to Taste and Smell
The revolutionary GLP-1 medications, celebrated for their efficacy in diabetes and weight management, are now being scrutinized for a less-discussed side effect: alterations in our senses of smell and taste. A recent study suggests a tangible link between these peptide therapies and sensory disturbances.
6 min read
Beyond Weight Loss: Surprising Health Benefits of GLP-1 Drugs
While widely recognized for their effectiveness in weight management, GLP-1 receptor agonists are revealing a spectrum of profound health benefits. Discover how these groundbreaking medications are impacting cardiovascular health, kidney function, liver disease, and even potentially neurodegenerative conditions.
7 min read
Semaglutide & Heart Health: New Insights on Atrial Fibrillation Prevention
Emerging research from Ben-Gurion University suggests Semaglutide and Colchicine may prevent atrial fibrillation by reducing inflammation and cardiac scarring.
8 min read
GLP-1 Supply Chain: How Shaily & Divi's Impact Drug Access
Two Indian firms are quietly powering the global GLP-1 weight loss boom. Learn how their manufacturing roles affect drug availability and therapy consistency.
8 min read
GLP-1 Drugs Show New Promise in Cardiovascular Procedures
New research suggests that GLP-1 receptor agonists, known for their roles in diabetes and weight management, may offer significant cardiovascular protection for patients undergoing complex procedures like TAVR and carotid artery stenting.
7 min read
Peptide Therapy & The Biohacking Boom: Navigating Unregulated Wellness
The world of biohacking is increasingly embracing peptides, but what's the reality behind the hype? This article delves into the science, the risks of unregulated substances, and the potential impact of regulatory changes on access to these compounds.
10 min read
Severe Obesity and Heart Failure: New Insights into Cardiac Muscle Recovery
A groundbreaking Johns Hopkins study reveals that severe obesity causes intrinsic cardiac muscle weakness, but weight loss can trigger significant recovery.
3 min read
GLP-1s Aid Health Even Without Weight Loss: New Evidence
While most people on GLP-1 medications like Wegovy experience significant weight loss, 10-15% are non-responders. Emerging research shows these drugs still improve liver health, reduce heart risks, and more—independent of weight changes. A new mouse study reveals why, challenging insurance requirements for weight loss thresholds.
5 min read
GLP-1 and SGLT2 Combo Cuts Mortality 29% in T2D Study
A large German study reveals that pairing GLP-1 receptor agonists with SGLT2 inhibitors significantly lowers all-cause mortality and cardiovascular risks in type 2 diabetes patients compared to SGLT2 inhibitors alone. Common combinations like dulaglutide plus empagliflozin showed a 29% mortality reduction. Experts highlight synergy but urge caution on potential harms.
5 min read
GLP-1s Benefit Non-Responders Without Weight Loss: New Evidence
While most people on GLP-1 medications like Wegovy experience dramatic weight loss, 10-15% are non-responders. Emerging research shows these drugs still deliver benefits for liver disease, heart health, and more—independent of the scale. A new study from Dr. Daniel Drucker's lab uncovers why.
5 min read
Genetic Mutations Linked to GLP-1 Drug Weight Loss and Side Effects
New studies uncover genetic variations in GLP1R and GIPR genes that predict better weight loss and higher side effect risks with GLP-1 drugs like Ozempic and Mounjaro. Cardiac protections from semaglutide appear separate from obesity reduction. A mouse study highlights noncoding DNA mutations' profound developmental impacts.
6 min read
Genetic Variations Linked to GLP-1 Weight Loss, Side Effects
New research from 23andMe reveals genetic variants in GLP1R that boost weight loss from GLP-1 drugs by up to 3.3 pounds. GIPR mutations increase vomiting risk on tirzepatide. Meanwhile, semaglutide's heart benefits appear independent of weight loss, opening doors to precision dosing.
5 min read
Cardiologist Sues UPMC; BP Control Stagnant; GLP-1 in Pregnancy
A prominent cardiologist has filed a whistleblower lawsuit against UPMC alleging racist texts and CEO conflicts. Meanwhile, U.S. blood pressure control remains below pre-pandemic levels, per new data. GLP-1 drugs during pregnancy show promising maternal benefits with no rise in fetal risks, according to a meta-analysis.
6 min read
Experts Stress Holistic Approach to Semaglutide for Weight Management
At a recent Pune meeting, experts from Pune and Mumbai underscored a holistic framework for Semaglutide use in weight management, especially as the drug goes off-patent in India. They stress pairing it with diet, exercise, and thorough patient assessments for lasting results in obesity and diabetes control. Generic versions now available for Rs 1,290 per month offer affordable access with proper precautions.
6 min read
How Drugs Like Ozempic Revolutionize Kidney Treatment
Chronic kidney disease affects over one in seven Americans, but new drugs like Ozempic are changing the game. GLP-1 receptor agonists, SGLT2 inhibitors, and finerenone offer additive benefits beyond traditional RAS inhibitors, potentially halting or reversing progression. Experts like Maarten Taal hail them as game-changers for kidney health.
5 min read
GLP-1 RAs Linked to Lower Mortality in Brain Metastases, T2DM Patients
For patients battling cancer with brain metastases and type 2 diabetes, GLP-1 receptor agonists may offer a survival edge. A retrospective study of over 19,000 patients found GLP-1 RA users had significantly lower all-cause mortality (HR 0.63) after matching. This benefit held across major cancers and most GLP-1 RA types.
5 min read
Ozempic May Lower Addiction Risk, New BMJ Study Shows
A groundbreaking BMJ study reveals GLP-1 drugs like Ozempic may reduce the risk of developing substance use disorders by 14% in diabetes patients. Among those with existing addictions, hospital admissions dropped 26%. While promising, these are associations from veteran health records—randomized trials are needed for proof.
5 min read
Semaglutide Could Slash Heart Tissue Damage Risk After Attack
Weight-loss injections like Ozempic and Wegovy, containing semaglutide, may protect the heart from severe tissue damage after a heart attack, according to new research. The study reveals how this GLP-1 medication prevents the dangerous 'no-reflow' phenomenon. Experts suggest it could even be administered by paramedics en route to the hospital.
5 min read
Wegovy and Ozempic May Slash Deadly Heart Attack Complication Risk
Researchers from the University of Bristol and UCL have found that GLP-1 drugs like Wegovy and Ozempic could dramatically reduce the risk of 'no-reflow,' a deadly complication affecting up to half of heart attack patients. By relaxing tiny blood vessels, these medications may prevent further heart damage even if given by paramedics on-site. This study opens doors for repurposing popular obesity and diabetes treatments in emergency cardiac care.
6 min read
Heart Disease in Women Projected to Rise 34% by 2050, AHA Warns
Without improved prevention, cardiovascular disease rates in U.S. women could climb from 10.7% in 2020 to 14.4% in 2050, warns the American Heart Association. Rising obesity, diabetes, and high blood pressure are key drivers, especially among younger women and underserved groups. Experts call for urgent action on early detection and lifestyle changes.
7 min read
Study: Ozempic, Wegovy NAION Risk Twofold Higher vs. SGLT2i Drugs
New research from Veterans' Affairs shows Ozempic and Wegovy users face double the risk of NAION—a serious vision loss condition—compared to SGLT2i drugs. Published in JAMA Ophthalmology, the study urges doctors to warn patients about potential permanent blindness from semaglutide-based GLP-1 medications. As lawsuits mount, understand the implications for diabetes and weight management.
5 min read
GLP-1 Activates KATP Channels in Coronary Pericytes for Cardioprotection
A new study in Nature Communications uncovers how GLP-1 activates ATP-sensitive potassium (KATP) channels in coronary pericytes, providing a novel cardioprotective mechanism through brain-gut-heart signaling. This discovery shifts focus from cardiomyocytes to the microvascular role of pericytes in enhancing myocardial blood flow. Understand the implications for GLP-1 receptor agonists in heart disease treatment.
7 min read
Mounjaro Sales Hit $7.4B as Regulators Ban Social Media Ads; Tirzepatide Link...
Eli Lilly reports Mounjaro sales skyrocketing to $7.4 billion in Q4 2026, driven by explosive GLP-1 demand. New 2026 research links tirzepatide to liver inflammation resolution and reduced heart failure risks. Meanwhile, UK regulators ban unauthorized social media promotions of these prescription drugs.
5 min read
Oral GLP-1s Benefit HF Patients: SOUL Trial Subanalysis
A subanalysis of the SOUL trial reveals that once-daily oral semaglutide (Rybelsus) lowers the risk of heart failure hospitalization, urgent visits, or CV death by 22% in patients with HF, diabetes, and ASCVD or CKD. Those with preserved ejection fraction (HFpEF) saw even greater protection at 41%. Experts highlight this as a key option for frail patients avoiding injections.
6 min read
Oral Semaglutide Reduces Heart Failure Risk in Type 2 Diabetes: SOUL Trial
New analysis from the SOUL trial reveals oral semaglutide significantly reduces heart failure risks in type 2 diabetes patients who already have the condition. This benefit is especially notable in HFpEF cases, without compromising safety. Discover the details and implications for managing cardiometabolic disease.
5 min read
GLP-1 Era Nutrition Symposium on Cardiac Recovery Held in Dhaka
A pivotal symposium on 'Nutrition in Clinical Practice: From GLP-1 Era to Cardiac Recovery' drew 150 nutrition professionals to Dhaka's KIB Convention Hall. Chaired by renowned dietician Akhtarun Nahar Alo, the event featured keynote speakers from NICVD and BIRDEM, followed by the launch of Nutricaa Limited's OPTIMA meal replacement. This gathering highlights the growing intersection of GLP-1 therapies and targeted nutrition for cardiac recovery.
5 min read
Oral Wegovy Pill: Novo Nordisk's Game-Changer for Obesity
Novo Nordisk's launch of an oral Wegovy pill marks a pivotal shift in GLP-1 therapy, offering a convenient alternative to injections for obesity treatment. This guide explores its mechanism, efficacy, safety profile, and how it stacks up against rivals like Eli Lilly's orforglipron. Learn what this means for your weight loss journey.
4 min read
Tirzepatide vs Semaglutide: Weight Loss Duration After Stopping
GLP-1 medications like semaglutide and tirzepatide deliver impressive weight loss, but what happens when you stop? Pivotal trials reveal significant regain risks, underscoring obesity as a chronic condition. This guide breaks down the evidence and offers practical insights for sustained results.
4 min read
GLP-1s and Muscle Loss: Evidence on Risks and Benefits
GLP-1 medications like semaglutide and tirzepatide deliver impressive weight loss, but fears of muscle wasting persist. Clinical evidence reveals these drugs cause modest, proportional lean mass changes while enhancing muscle quality. Discover the science and practical steps to optimize outcomes.
4 min read
Novo Nordisk vs Eli Lilly: GLP-1 Drugs Showdown
Novo Nordisk and Eli Lilly dominate the GLP-1 market with powerhouse drugs like Wegovy and Zepbound. But which offers better weight loss results, tolerability, and future potential? This guide breaks down the science, clinical trials, and real-world factors to help you decide.
5 min read
Scotland GLP-1 Costs Surge: Mounjaro Price Hike Impact
Scotland's NHS spending on GLP-1 weight-loss injections like Mounjaro has skyrocketed to nearly £3 million monthly, fueled by surging prescriptions and a sudden Mounjaro price hike tied to US policy. These drugs offer profound benefits beyond weight loss, reducing risks of heart disease and more. Here's what patients need to know about access, costs, and real-world impact.
4 min read
Why Ozempic & GLP-1s Cost More in the US: A Guide
A 54-year-old father walked away from his $997 Ozempic prescription due to sky-high costs. GLP-1 medications like Ozempic and Mounjaro offer transformative benefits for diabetes and obesity, yet US prices make them unaffordable for millions. This guide breaks down the pricing crisis, clinical value, and paths to reform.
4 min read
Prof Urges Caution on Funding Wegovy Rollout
Prof Jim Mann cautions against broad funding for Wegovy, urging focus on high-risk patients like those with heart disease or diabetes. He emphasizes integrating GLP-1 medications into a national obesity strategy with mandatory nutritional support to prevent weight regain. Early data highlights side effect risks and the need for dietary counseling.
2 min read
Study: GLP-1s Reduce Mortality, Events in Sickle Cell Disease
GLP-1 receptor agonists significantly reduced all-cause mortality and key adverse events in sickle cell disease patients, per ASH Annual Meeting data. Researchers matched cohorts using TriNetX, showing benefits across primary and secondary outcomes. These hypothesis-generating findings warrant prospective trials.
2 min read
Cardiologist: GLP-1 Drugs Benefits Beyond Weight Loss for Heart, Liver
Cardiologist Dmitry Yaranov states GLP-1 drugs like Ozempic, Wegovy, and Mounjaro offer benefits far beyond weight loss. They enhance cardiovascular health, combat fatty liver disease, and improve blood sugar control in diabetes patients. These medications could redefine treatment for heart, liver, and metabolic diseases.
1 min read
GLP-1 Receptor Agonists and Next-Generation Metabolic Hormone Therapies for Chronic Kidney Disease
Clinical trials across the cardiovascular-kidney-metabolic spectrum demonstrate kidney protective effects of incretin-based therapies. Multiple studies show GLP-1RAs and dual GIP/GLP-1RAs reduce kidney disease progression, albuminuria, and kidney failure risk in patients with type 2 diabetes and chronic kidney disease.
10 min read
GLP-1s: Understanding the Evolution of Weight-Loss Medications
Weight-loss drugs, particularly those mimicking GLP-1, have gained significant traction. This article delves into their functionality, efficacy, side effects, accessibility challenges, and the emergence of more accessible pill versions.
6 min read
My Start GLP-1 Reviews: U.S. Doctors, Fast Delivery, and Honest Experience
This review examines MyStart GLP-1, focusing on its claims of quick access, U.S.-based doctors, and fast delivery. It delves into the program's structure, support system, and overall user experience to provide clarity for those considering this option.
10 min read
Mounjaro Delivered: UAE App Introduces Weight-Loss Medication Delivery
A prominent home services company in the UAE has begun delivering weight-loss medications, indicating the sustained popularity of GLP-1 drugs. This move raises discussions about accessibility and safety when obtaining prescription drugs online.
4 min read
Real-World Data Highlights Heart Benefits of Diabetes Drugs Semaglutide and Tirzepatide
New research indicates that semaglutide and tirzepatide, drugs used for managing type 2 diabetes, exhibit heart-protective effects in real-world settings, mirroring findings from clinical trials. The study highlights the cardiovascular benefits these medications offer to patients in everyday clinical practice.
4 min read